Frederick Leslie Greene

Frederick Leslie Greene

Auto-generated profile, based on publicly available information

Frederick Leslie Greene

Levine Cancer Institute

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2016
Verified
Book Chapter
Open access
MAMahul B. Amin
Mahul B. Amin
SEStephen B. Edge
Stephen B. Edge
FGFrederick L. Greene
Frederick L. Greene
DBDavid R. Byrd
David R. Byrd
RBRobert K. Brookland
Robert K. Brookland
LVLaura Meyer Vega
Laura Meyer Vega

1 October 2002 in Annals of Surgery
Verified
Journal Article
Closed access
FGFrederick L. Greene
Frederick L. Greene
ASAndrew K. Stewart
Andrew K. Stewart
HNH. James Norton
H. James Norton
To analyze a large cohort of patients with stage III colon cancer to determine whether subgroup stratification better defines outcome. The Tumor (T), Node (N), Metastasis (M) system is based on depth of tumor invasion into the colonic wall, the number of regional lymph nodes involved, and distant metastasis. Traditionally, colon cancer has been designated as stage III based on nodal involvement regardless of the depth (T1–4) of tumor penetration. Treatment decisions have been based on nodal involvement with less emphasis on colonic wall penetration in stage III patients. Patients (n = 50,042) with stage III colon cancer reported to the National Cancer Data Base from 1987 through 1993 were analyzed. Observed survival was calculated by actuarial life table methods for three new node-positive subgroups (IIIA: T1/2, N1; IIIB: T3/4, N1; IIIC: any T, N2). The Cox proportional hazards model was used to test the prognostic strength of selected covariates. Three distinct subcategories within a traditional stage III cohort of colonic cancer were identified. Five-year observed survival rates for these three subcategories were 59.8%, IIIA; 42.0%, IIIB; and 27.3%, IIIC. Differences between subgroups were significant (P < .0001). Similar differences were calculated after stratification for treatment. A multivariate proportional hazards model identified the new stage III subgroups, modality of the first course of therapy, patient age, and tumor grade as significant independent prognostic covariates. The current stage III designation of colon cancer excludes prognostic subgroups stratified for mural penetration (T1–4) or nodal involvement (N1 vs. N2). Analysis of a large data set supports stratification into three subsets, confirming the benefit of adjuvant chemotherapy in each subgroup. This strategy should be used in the reporting and staging of node-positive colon cancers.

17 March 2009 in Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
FGFrederick L. Greene
Frederick L. Greene
LSLeslie H. Sobin
Leslie H. Sobin
Click on the article title to read more.

20 June 2002 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
FGFrederick L. Greene
Frederick L. Greene
LSLeslie H. Sobin
Leslie H. Sobin

15 May 2004 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FGFrederick L. Greene
Frederick L. Greene
ASAndrew K. Stewart
Andrew K. Stewart
HNH. James Norton
H. James Norton
Purpose: The tumor-node-metastasis system for staging rectal cancer is based on invasion, number of involved nodes, and metastasis. Nodes are classified as N1 or N2 according to the number involved with metastases. Nodal positivity defines stage III regardless of depth of invasion or number of positive nodes. Our purpose was to analyze overall survival when node-positive patients were stratified into three new subsets. Methods: We analyzed data entered into the National Cancer Data Base for 5,987 stage III patients with rectal cancer between 1991 and 1993. Survival was calculated using three new subgroups (IIIA: T1/2, N1; IIIB: T3/4, N1; IIIC: any T, N2). Survival following surgery and adjuvant therapy was assessed. The observed survival rates were calculated and compared using the log-rank method. The Cox regression model assessed subgroup differences. Results: Five-year observed survival rates for stage III subcategories were 55.1% in IIIA; 35.3% in IIIB; and 24.5% in IIIC. Stratifying for treatment outcome, stage IIIA patients having surgery alone (n = 278) had poorer observed 5-year survival (39%) than patients treated with surgery and adjuvant chemotherapy or radiation therapy (chemo/XRT; n = 765; 60%). Similar outcomes occurred in IIIB (surgery-alone [n = 726; 21.7%] and chemo/XRT [n = 2,130; 40.9%] groups) and in IIIC (surgery-alone [n = 467; 12.2%] and chemo/XRT [n = 1,621; 28.9%] groups). Differences were significant (P < .0001) in all stages. Conclusion: The traditional stage III designation of rectal cancer fails to account for invasion (T1-4) and number of involved nodes (N1, N2). The stratification of stage III patients into three subsets should be used in future analyses of rectal cancer. The effect of postoperative adjuvant therapy was beneficial in all subsets.

1 January 2003 in Seminars in Surgical Oncology
Verified
Journal Article
Closed access
PDF file
FGFrederick L. Greene
Frederick L. Greene